AppliedXL and Bain Introduce a New Operating Discipline for Pharma

Key Takeaways

• Operational execution is a major driver of R&D productivity, yet traditionally hard to measure
• AppliedXL's structured intelligence makes operational drift visible, comparable, and predictive
• Disease areas differ materially in execution difficulty, NSCLC presents the largest operational burden
• Companies display consistent execution 'postures' independent of therapeutic area
• AI + human expertise creates a durable operating discipline for competitive advantage

Why Operational Performance Matters

Biopharma has long focused on scientific probability of success and financial return when evaluating R&D productivity. Operational performance, the ability to run predictable and timely clinical programs, receives far less scrutiny despite its impact on cost, timelines, and portfolio value.

The main limitation has been the absence of consolidated, real-time clinical intelligence. AppliedXL's structured dataset changes this by making operational behavior observable and comparable across companies and therapeutic areas.

What AppliedXL Makes Visible

AppliedXL aggregates trial-level signals into a unified system, including:

• Timeline changes

• Enrollment increases or slowdowns

• Protocol adjustments

• Status shifts across sites and geographies

Earlier analyses showed that these signals can anticipate program failure. This collaboration with Bain applies the same structured intelligence to measure 'trial delivery', meaning how closely execution aligns with the original plan.

The Analytical Framework

The joint framework evaluates trial delivery across two dimensions:

A. Disease-Area Complexity

Certain therapeutic areas create higher operational drag. Bain and AppliedXL examined three distinct areas, Atopic Dermatitis, NSCLC, and Heart Failure, across all US-based trials.

Metrics included: percentage of trials delayed, duration of delays, frequency of timeline or protocol changes, and enrollment volatility.

Findings: NSCLC showed the highest delay rates and the longest slippage. AD trials had more frequent design changes. Enrollment behavior was similar across areas, but NSCLC required significantly larger increases in patient numbers.

B. Company Execution Posture

A composite delivery score captured delay frequency, delay size, and enrollment shifts across sponsors.

Key insight: Companies displayed remarkably consistent execution behavior across therapeutic areas. Each organization exhibited a stable 'posture,' ranging from conservative zero-defect planning to more flexible, change-driven operating models.

Human Expertise Still Matters

Both dimensions reinforce a key point: AI surfaces operational drift, but human experts translate these signals into actionable decisions.

• Therapeutic-area specialists interpret whether a delay is structural, avoidable, or strategically insignificant

• Strategists compare company-level postures and identify where trial design or operational models need intervention

This pairing creates an integrated approach: AI detects patterns early; experts judge what to do next.

What This Enables for Leaders

With detailed operational signals available in real time, clinical development and operations teams can:

• Benchmark performance against disease-area norms

• Forecast risks earlier in the trial lifecycle

• Adapt protocols before delays compound

• Allocate resources based on execution posture rather than assumptions

• Compare sponsors objectively during partnerships, licensing, or M&A evaluations

The same methodology extends to recruitment analysis using AppliedXL's enrollment timelines.

Conclusion

The framework can guide planning, investment decisions, partnerships, and portfolio management, unlocking a new lever for competitive advantage in clinical development.